ME2303

ME2303 is a **fluorine-containing anthracycline derivative** developed as an investigational antitumor agent. It has demonstrated superior antitumor activity compared to adriamycin (doxorubicin) in various preclinical models, including colon adenocarcinoma, Lewis lung carcinoma, and multidrug-resistant leukemia and solid tumor models. ME2303 appears to be rapidly metabolized and cleared from plasma and liver but accumulates and persists in tumor tissues, where its conversion to active metabolites (notably M1: 7-O-(2,6-dideoxy-2-fluoro-α-L-talopyranosyl)adriamycinone) may contribute to its marked antitumor effects. It is notably active against Adriamycin- and vincristine-resistant cells and tumor models, showing distinct advantages in preclinical efficacy and resistance profile.

Other names

7-O-(2,6-dideoxy-2-fluoro-α-L-talopyranosyl)adriamycinone-14-hemipimerate